Fenbendazole for Colorectal & Pancreatic Cancer
What Research Shows
From:
Gastrointestinal cancers — colorectal, pancreatic, and hepatocellular — are among the most-discussed cancer types in online fenbendazole communities. On social media forums dedicated to repurposed drug research, questions about FBZ and colon cancer, pancreatic cancer, and liver cancer appear daily, driven in part by the extreme difficulty of treating these cancers with conventional approaches alone. Colorectal cancer is the third most diagnosed cancer worldwide and the second leading cause of cancer death. Pancreatic cancer carries a five-year survival rate under 12%. These grim statistics have driven patients and researchers alike to explore every available avenue, including benzimidazole antiparasitics.
This article synthesizes preclinical and early clinical evidence on fenbendazole and its benzimidazole relatives across three GI cancer types: colorectal cancer (CRC), pancreatic cancer (PC), and hepatocellular carcinoma (HCC). We cover cell cycle arrest data from a 2022 AACR abstract, the unique finding that FBZ retains activity in 5-fluorouracil-resistant CRC cells via p53-independent ferroptosis, parbendazole + gemcitabine synergy in pancreatic cancer, and the UCSF liver cancer benzimidazole research. We also examine a 2026 safety case report from a patient with metastatic colon cancer that offers important lessons on monitoring and dose escalation.
⚠️ Educational Disclaimer
This article is for research and informational purposes only. It does not constitute medical advice and is not a substitute for professional oncology consultation. Always discuss any investigational protocol with your physician before making any treatment decisions.
Why GI Cancers Are at the Center of FBZ Research
The gastrointestinal tract is a particularly relevant site for benzimidazole pharmacology. Orally administered benzimidazoles, such as fenbendazole, are absorbed from the GI tract, meaning intestinal and colonic tissues are exposed to relatively higher local concentrations than many other tissues. This has led researchers to examine whether these drugs might be particularly relevant to GI-originating tumors.
Beyond pharmacokinetics, GI cancers share several biological features that align with FBZ’s known mechanisms of action:
High proliferative rate: Colorectal tumors are driven by rapid epithelial cell turnover, making cell cycle disruption especially relevant.
Chemotherapy resistance: Both colorectal (5-FU resistance) and pancreatic (gemcitabine resistance) cancers are notorious for developing resistance to first-line agents.
Metabolic dependency: GI cancers show strong reliance on glucose metabolism and microtubule-driven cell division — two pathways benzimidazoles target directly.
p53 mutations: Common in colorectal and pancreatic cancers, yet fenbendazole retains activity through p53-independent pathways, which is a significant mechanistic finding.
Read the full article: https://www.sanarelab.science/fenbendazole-colorectal-pancreatic-cancer/